Pharma Focus Asia

CytomX Therapeutics Announces Probody® T-Cell Engaging Bispecific (TCB) Achievement in Collaboration with Astellas

Friday, January 27, 2023

CytomX Therapeutics, Inc today announced that it has achieved a clinical candidate milestone under its TCB agreement with Astellas. The clinical candidate is the first Probody® TCB molecule to progress in the collaboration and will trigger a $5 million dollar milestone payment to CytomX. CytomX and Astellas are also collaborating on other conditionally activated TCB programmes with CytomX eligible to receive future preclinical, clinical and commercial milestones.

Localising T-cell activity to the tumour microenvironment could result in important breakthroughs for patients, and the Probody® platform has potential to address this challenge.

CytomX partnership with Astellas will continue in advancing novel TCBs towards the clinic to make a significant contribution in bringing the power of T-cell engaging therapies to a broader set of patients with cancer.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024